Your browser doesn't support javascript.
loading
Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: biochemical and electrophysiological characterization.
Malherbe, Pari; Knoflach, Frédéric; Marcuz, Anne; Bohnert, Claudia; Weber, Michael; Knust, Henner; Ratni, Hasane; Spooren, Will; Ballard, Theresa M; Bissantz, Caterina.
Afiliação
  • Malherbe P; Discovery Neuroscience, F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Grenzacherstrasse 124, CH4070, Basel, Switzerland. Electronic address: pari.malherbe@bluewin.ch.
  • Knoflach F; Discovery Neuroscience, F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Grenzacherstrasse 124, CH4070, Basel, Switzerland.
  • Marcuz A; Discovery Neuroscience, F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Grenzacherstrasse 124, CH4070, Basel, Switzerland.
  • Bohnert C; Discovery Neuroscience, F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Grenzacherstrasse 124, CH4070, Basel, Switzerland.
  • Weber M; Discovery Neuroscience, F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Grenzacherstrasse 124, CH4070, Basel, Switzerland.
  • Knust H; Discovery Chemistry, F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Grenzacherstrasse 124, CH4070, Basel, Switzerland.
  • Ratni H; Discovery Chemistry, F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Grenzacherstrasse 124, CH4070, Basel, Switzerland.
  • Spooren W; Discovery Neuroscience, F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Grenzacherstrasse 124, CH4070, Basel, Switzerland.
  • Ballard TM; Discovery Neuroscience, F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Grenzacherstrasse 124, CH4070, Basel, Switzerland.
  • Bissantz C; Discovery Chemistry, F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Grenzacherstrasse 124, CH4070, Basel, Switzerland.
Neuropharmacology ; 86: 259-72, 2014 Nov.
Article em En | MEDLINE | ID: mdl-25107588
ABSTRACT
The NK3 receptor is a GPCR that is prominently expressed in limbic areas of the brain, many of which have been implicated in schizophrenia. Phase II clinical trials in schizophrenia with two selective NK3 antagonists (osanetant and talnetant) have demonstrated significant improvement in positive symptoms. The objective of this study was to characterize the properties of a novel dual NK2/NK3 antagonist, RO5328673. [(3)H]RO5328673 bound to a single saturable site on hNK2, hNK3 and gpNK3 with high-affinity. RO5328673 acted as an insurmountable antagonist at both human and guinea-pig NK3 receptors in the [(3)H]IP accumulation assay. In binding kinetic analyses, [(3)H]RO5328673 had fast association and dissociation rates at hNK2 while it had a fast association rate and a remarkably slow dissociation rate at gp and hNK3. In electrophysiological recordings of gp SNpc, RO5328673 inhibited the senktide-induced potentiation of spontaneous activity of dopaminergic neurons with an insurmountable mechanism of action. RO5328673 exhibited in-vivo activity in gerbils, robustly reversing the senktide-induced locomotor activity. The TM2 residue gpNK3-A114(2.58) (threonine in all other species) was identified as the critical residue for the RO5328673's slower dissociation kinetics and stronger insurmountable mode of antagonism in the guinea-pig as compared to hNK3-T139(2.58). Using site-directed mutagenesis, [(3)H]RO5328673 binding and rhodopsin-based modeling, the important molecular determinants of the RO5328673-binding pocket of hNK3 were determined. A comparison of the RO5328673-binding pocket with that of osanetant showed that two antagonists have similar contact sides on hNK3 binding crevice except for three mutations V95L(1.42), Y247W(5.38), V255I(5.46), which behaved differently between interacting modes of two antagonists in hNK3.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Carbamatos / Receptores da Neurocinina-3 / Neurotransmissores Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Carbamatos / Receptores da Neurocinina-3 / Neurotransmissores Idioma: En Ano de publicação: 2014 Tipo de documento: Article